Posted by Michael Wonder on 18 Oct 2022
IntelGenx submits response to CRL from FDA for Rizaport VersaFilm
18 October 2022 - IntelGenx today announced that it has responded to the complete response letter for its 505(b)(2) new drug application for Rizaport VersaFilm received from the US FDA in March 2020.
